Clinical Efficacy of Conservative Treatment in Female Patients With Plevic Congestion Syndrome

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04512443

Enrollment

Registered

2020-08-13

Start date

2019-12-28

Completion date

2020-03-28

Last updated

2020-08-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pelvic Congestion Syndrome

Brief summary

The article presents the results of a randomized, placebo-controlled study of the conservative treatment with Daflon (Detralex) in female patients with Pelvic congestion syndrome .

Interventions

DRUGDaflon

All consecutive patients were randomly allocated into 2 groups to receive Daflon (Detralex) at a dose of 1000 mg once daily (study group) or placebo (control group).

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

•The presence of pelvic varicose veins verified by transvaginal and transabdominal duplex ultrasound scanning

Exclusion criteria

* Severe disease of the gastrointestinal tract or hematopoietic system * Terminal stage of cardiovascular, respiratory, renal or hepatic failure * Grade IV malignancy * Peripheral artery disease (PAD) of the lower extremities, any type of diabetes, or mental disease. * Pregnant women at any gestational age, women who gave birth less than 12 months ago, and breastfeeding mothers.

Design outcomes

Primary

Measure	Time frame	Description
Pelvic Varicose Veins Questionnaire	2 months	Assessment of quality of life according to the questionnaire before and after treatment

Countries

Russia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026